Opinion|Videos|April 26, 2024

TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma

Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.


Latest CME